Chromium treatment has no effect in patients with type 2 diabetes in a western population: A randomized, double-blind, placebo-controlled trial

Diabetes Care

Volumn 30, Issue 5, 2007, Pages 1092-1096

  Kleefstra, Nanne ^a,b   Houweling, Sebastiaan T ^b   Bakker, Stephan J L ^c   Verhoeven, Simon ^b   Gans, Rijk O B ^c   Meyboom De Jong, Betty ^d   Bilo, Henk J G ^a,c  

^a ISALA HOSPITAL   (Netherlands)

^b LANGERHANS MEDICAL RESEARCH GROUP   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CHROMIUM; GLYCOSYLATED HEMOGLOBIN; PLACEBO;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BODY FAT; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; CHROMIUM; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LIPIDS; MALE; MIDDLE AGED; NETHERLANDS; PLACEBOS; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 34247618258     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc06-2192     Document Type: Article

References (31)

1. Amos AF, McCarty DJ, Zimmet P: The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 14:S7-S85, 1997
2. Kannel WB, McGee DL: Diabetes and cardiovascular disease: the Framingham study. JAMA 241:2035-2038, 1979
3. King H, Aubert RE, Herman WH: Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 21:1414-1431, 1998
4. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288:2709-2716, 2002
5. Schwarz K, Mertz W: A glucose tolerance factor and its differentiation from factor 3. Arch Biochem Biophys 72:515-518, 1957
6. Shindea UA, Sharma G, Xu YJ, Dhalla NS, Goyal RK: Insulin sensitising action of chromium picolinate in various experimental models of diabetes mellitus. J Trace Elem Med Biol 18:23-32, 2004
7. Davis CM, Vincent JB: Chromium oligopeptide activates insulin receptor tyrosine kinase activity. Biochemistry 36:4382-4385, 1997
8. Sun Y, Ramirez J, Woski SA, Vincent JB: The binding of trivalent chromium to low-molecular-weight chromium-binding substance (LMWCr) and the transfer of chromium from transferrin and chromium picolinate to LMWCr. J Biol Inorg Chem 5:129-136, 2000
9. Anderson RA, Cheng N, Bryden NA, Polansky MM, Chi J, Feng J: Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes 46:1786-1791, 1997
10. Althuis MD, Jordan NE, Ludington EA, Wittes JT: Glucose and insulin responses to dietary chromium supplements: a meta-analysis. Am J Clin Nutr 76:148-155, 2002
11. Yeh GY, Eisenberg DM, Kaptchuk TJ, Phillips RS: Systematic review of herbs and dietary supplements for glycemic control in diabetes. Diabetes Care 26:1277-1294, 2003
12. Manygoats KR, Yazzie M, Stearns DM: Ultrastructural damage in chromium picolinate-treated cells: a TEM study: transmission electron microscopy. J Biol Inorg Chem 7:791-798, 2002
13. Stearns DM, Silveira SM, Wolf KK, Luke AM: Chromium(III) tris(picolinate) is mutagenic at the hypoxanthine (guanine) phosphoribosyltransferase locus in Chinese hamster ovary cells. Mutat Res 15:135-142, 2002
14. Slesinski RS, Clarke JJ, San RH, Gudi R: Lack of mutagenicity of chromium picolinate in the hypoxanthine phosphoribosyltransferase gene mutation assay in Chinese hamster ovary cells. Mutat Res 585:86-95, 2005
15. Agency revises chromium picolinate advice [article online], 2004. Available from http://www.food.gov.uk/news/newsarchive/2004/dec/chromiumupdate. Accessed 2 October 2006
16. Li YC: Effects of brewer's yeast on glucose tolerance and serum lipids in Chinese adults. Biol Trace Elem Res 41:341-347, 1994
17. Offenbacher EG, Rinko CJ, Pi-Sunyer FX: The effects of inorganic chromium and brewer's yeast on glucose tolerance, plasma lipids, and plasma chromium in elderly subjects. Am J Clin Nutr 42:454-461, 1985
18. Offenbacher EG, Pi-Sunyer FX: Beneficial effect of chromium-rich yeast on glucose tolerance and blood lipids in elderly subjects. Diabetes 29:919-925, 1980
19. Racek J, Trefil L, Rajdl D, Mudrova V, Hunter D, Senft V: Influence of chromium-enriched yeast on blood glucose and insulin variables, blood lipids, and markers of oxidative stress in subjects with type 2 diabetes mellitus. Biol Trace Elem Res 109:215-230, 2006
20. Bahijri SM, Mufti AM: Beneficial effects of chromium in people with type 2 diabetes, and urinary chromium response to glucose load as a possible indicator of status. Biol Trace Elem Res 85:97-109, 2002
21. Moher D, Schulz KF, Altman DG: The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 357:1191-1194, 2001
22. El Assaad MA, Topouchian JA, Asmar RG: Evaluation of two devices for self-measurement of blood pressure according to the international protocol: the Omron M5-I and the Omron 705IT. Blood Press Monit 8:127-133, 2003
23. Deurenberg P, Andreoli A, Borg P, Kukkonen-Harjula K, de Lorenzo A, van Marken Lichtenbelt WD, Testolin G, Vigano R, Vollaard N: The validity of predicted body fat percentage from body mass index and from impedance in samples of five European populations. Eur J Clin Nutr 55:973-979, 2001
24. Asplund J, Danielson M, Ohman P: Patients compliance in hypertension - the importance of number of tablets. Br J Clin Pharmacol 17:547-552, 1984
25. Lebovits AH, Strain JJ, Schleifer SJ, Tanaka JS, Bhardwaj S Messe MR: Patient non-compliance with self-administered chemotherapy. Cancer 65:17-22, 1990
26. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419, 1985
27. Ghosh D, Bhattacharya B, Mukherjee B, Manna B, Sinha M, Chowdhury J, Chowdhury S: Role of chromium supplementation in Indians with type 2 diabetes mellitus. J Nutr Biochem 13:690-697, 2002
28. Gunton JE, Cheung NW, Hitchman R, Hams G, O'Sullivan C, Foster-Powell K, McElduff A: Chromium supplementation does not improve glucose tolerance, insulin sensitivity, or lipid profile: a randomized, placebo-controlled, double-blind trial of supplementation in subjects with impaired glucose tolerance. Diabetes Care 28:712-713, 2005
29. Kleefstra N, Houweling ST, Jansman FG, Groenier KH, Gans RO, Meyboom-de Jong B, Bakker SJ, Bilo HJ: Chromium treatment has no effect in patients with poorly controlled, insulin-treated type 2 diabetes mellitus in a Western population: a randomized, double blind, placebo-controlled trial. Diabetes Care 29:521-525, 2006
30. Martin J, Wang ZQ, Zhang XH, Wachtel D, Volaufova J, Matthews DE, Cefalu WT: Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes. Diabetes Care 29:1826-1832, 2006
31. Kleefstra N, Bilo HJ, Bakker SJ, Houweling ST: [Chromium and insulin resistance]. Ned Tijdschr Geneeskd 148:217-220, 2004 (in Dutch)